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Abstract The thioredoxin system is one of the major thiol
reducing systems of the cell. Recent studies have revealed that
Plasmodium falciparum and human thioredoxin reductase
represent a novel class of enzymes, which are substantially
different from the isofunctional prokaryotic Escherichia coli
enzyme. We identified the cysteines Cys88 and Cys93 as the redox
active disulfide and His509 as the active site base [Gilberger,
T.-W., Walter, R.D. and Muºller, S., J. Biol. Chem. 272 (1997)
29584^29589]. In addition to the active site thiols Cys88 and
Cys93 the P. falciparum enzyme has another pair of cysteines at
the C-terminus: Cys535 and Cys540. To assess the possible role of
these peripheral cysteines in the catalytic process the single
mutants PfTrxRC535A and PfTrxRC540A, the double mutant
PfTrxRC535AC540A and the deletion mutant PfTrxRv9 (C-
terminal deletion of the last nine amino acids) were constructed.
All mutants are defective in their thioredoxin reduction activity,
although they still show reactivity with 5,5P-dithiobis (2-
nitrobenzoate). These data imply that the C-terminal cysteines
are crucially involved in substrate coordination and/or electron
transfer during reduction of the peptide substrate.
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1. Introduction
Thioredoxin reductase (TrxR) is a homodimeric protein
which belongs to the family of pyridine nucleotide-disul¢de
oxidoreductases like lipoamide dehydrogenase and gluta-
thione reductase (GR) [1]. In general the members of this
group of proteins show a high degree of similarity at the
molecular and mechanistic levels irrespective of their source.
However, this does not apply to TrxRs, which can be sepa-
rated into at least two classes: low Mr and high Mr TrxRs.
These proteins di¡er not only in their primary structures but
also in their subunit molecular mass and their proposed re-
action mechanisms [2^5]. The Escherichia coli TrxR is a rep-
resentative of the low Mr TrxRs and its reaction mechanism
has been investigated in great detail [6^8]. In order to react
with its substrate the enzyme has to undergo a conformational
change. The reaction mechanism of high Mr TrxRs is com-
pletely di¡erent from that of low Mr TrxRs and resembles
that of glutathione reductase and lipoamide dehydrogenase
[4,5]. Remarkably, the proteins from human placenta, lung
adenocarcinoma cells and human T-cells possess a penulti-
mate C-terminal selenocysteine residue (SeCys) adjacent to a
cysteine residue [9^11] which represents an additional poten-
tially redox-active component in the mammalian TrxRs [4].
The Plasmodium falciparum protein, however, does not con-
tain a SeCys but possesses a C-terminal extension (Table 1),
including two cysteine residues which are separated by four
amino acids rather than being adjacent, as found in the mam-
malian TrxRs. The occurrence of a C-terminal cysteine pair is
reminiscent of another member of the £avin disul¢de oxido-
reductase family, the mercuric ion reductases [12] (Table 1). It
has been shown that these residues (Cys558 and Cys559) are
essential for a high level of mercuric ion reductase activity
[12^14].
Considering these facts the PfTrxR with its extended C-
terminus and the terminal cysteine residues Cys535 and
Cys540 suggests the possibility of an involvement of these pe-
ripheral amino acids in the catalytic mechanism of this high
Mr TrxR. To elucidate the role of Cys535 and Cys540 for cat-
alysis of PfTrxR we performed mutagenesis studies and char-
acterized the recombinantly expressed PfTrxR mutant pro-
teins.
2. Materials and methods
2.1. Mutagenic oligonucleotides and site-directed mutagenesis
The mutagenic oligonucleotides used to generate the mutant con-
structs are shown in Table 2. Two di¡erent in vitro mutagenesis
methods were applied. The site-directed exchange of amino acids
was performed as previously described [5,15]. All mutant constructs
were analyzed performing the Sanger dideoxy chain termination re-
action for double stranded DNA [16].
The C-terminal deletion mutant was generated by PCR using Pfu
DNA polymerase (Stratagene). The antisense oligonucleotide v9 was
designed with a BamHI restriction site resulting in a transcription
termination at the respective site of the coding region of PfTrxR
(Table 2). The 5P sense oligonucleotide contained a HindIII restriction
site and encodes the ¢rst eight amino acids of PfTrxR (Table 2). The
PCR (50 Wl) contained 50 ng of the double stranded, supercoiled
expression plasmid pJC40PfTrxR [3] and 100 ng mutagenic sense
and antisense primer, deoxyribonucleotides, reaction bu¡er and Pfu
DNA polymerase according to the manufacturer’s recommendations
(Stratagene). PCR used the following protocol: 95‡C (1 min) follow-
ing 30 cycles of 95‡C (30 s), 55‡C (1 min), 68‡C (3 min). The isolated
PCR product was restricted with BamHI and HindIII and subcloned
into pJC20 [17], previously digested with BamHI and HindIII (Boehr-
inger Mannheim). The ligation product was used to transform E. coli
BL 21 (DE3). The mutant was analyzed performing the Sanger di-
deoxy chain termination reaction for double stranded DNA [16].
2.2. Expression and puri¢cation of P. falciparum thioredoxin reductases
The expression plasmid pJC20 [17] which contains a T7 promoter
was used for overexpression of the wild-type PfTrxR and all mutants
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in E. coli BL21 (DE3) cells. E. coli BL 21 (DE3) cells carrying the
expression plasmid containing the mutated cDNA were grown over-
night at 37‡C in Luria-Bertani medium (containing 50 Wg/ml ampicil-
lin). Expression was carried out in a 2 liter high density fermenter. 300
ml of the overnight culture was added to 1.2 liter of terri¢c broth
medium [16]. The cultures were grown at 37‡C to an OD600 of 3,
subsequently 500 ml of terri¢c broth medium, 50 Wg/ml ampicillin
and 1 mM isopropyl L-D-thiogalactoside were added to the cultures.
The cells were harvested 3 h after induction by centrifugation
(4000Ug ; 10 min) and sonicated (Soni¢er 250, Branson) in 50 mM
potassium phosphate bu¡er pH 7.6 containing 1 mM EDTA (bu¡er
A). The recombinant proteins were puri¢ed as previously described
[18,19], with modi¢cations. The cell lysate was centrifuged at
100 000Ug for 1 h (Centrikon 1065, Kontron). The resulting super-
natant was saturated to 40% with ammonium sulfate, the precipitated
protein removed by centrifugation and overexpressed PfTrxR wild-
type and mutant proteins were precipitated by saturating the super-
natant to 70% ammonium sulfate. The precipitate was dissolved in
bu¡er A and dialyzed against two changes of the same bu¡er over-
night. Subsequently, the protein was applied to 2P,5P-ADP agarose
(Sigma) previously equilibrated with bu¡er A and washed with the
same bu¡er until no more protein was detected in the £ow through.
Non-speci¢cally bound protein was washed o¡ the resin with bu¡er A
containing 0.1 M KCl and PfTrxR wild-type and mutant proteins
were eluted with bu¡er A containing 0.1 M KCl and 1 mM NADP.
In order to improve the purity of the protein and to remove the
NADP, the fractions with highest 5,5P-dithiobis (2-nitrobenzoate)
(DTNB)-reducing activity were pooled and supplied to a Sephadex
S-200 FPLC column (Pharmacia, Freiburg) previously equilibrated
with bu¡er A. The purity of the recombinant proteins was assessed
by SDS-PAGE.
2.3. Expression and puri¢cation of E. coli thioredoxin
E. coli thioredoxin was recombinantly expressed in E. coli by using
the plasmid pDL59Tv4 containing the trxA gene (E. coli thioredoxin)
(S.B. Mulrooney, 1997, unpublished) kindly provided by C.H. Wil-
liams Jr., Ann Arbor, MI, USA. The peptide was puri¢ed according
to D. Veine and C.H. Williams Jr. (personal communication). The
purity of the recombinant E. coli thioredoxin was checked on a
15% SDS-PAGE; for quanti¢cation the extinction at 280 nm
(13 700 M31 cm31) was used.
2.4. FAD contents and extinction coe⁄cients
The extinction coe⁄cients of protein bound FAD in the 450 nm
region were determined for all PfTrxRs as previously described [5,20].
Values are means of three determinations and were used for protein
quanti¢cation: PfTrxR 12.49 þ 0.34 mM31 cm31, PfTrxRC535A
12.04 þ 0.52 mM31 cm31, PfTrxRC540A 13.55 þ 0.30 mM31 cm31,
PfTrxRC535AC540A 12.30 þ 0.22 mM31 cm31, PfTrxRv9
12.29 þ 0.08 mM31 cm31.
2.5. Spectral analysis
Oxidized and NADPH reduced absorption spectra of wild-type and
PfTrxRC535AC540A were recorded in a thermostatted spectro-
photometer (Uvikon 932, Kontron) at 22‡C as previously described
[5].
2.6. Thioredoxin reductase activity
The kinetic parameters of wild-type PfTrxR and all mutant proteins
were determined by the DTNB reduction assay and the thioredoxin
reduction assay [3,18,21] using E. coli thioredoxin (Trx-S2) as a sub-
strate. The thioredoxin reduction assay mixture (1 ml) contained 100
mM HEPES-NaOH bu¡er, pH 7.6, 2 mM EDTA, 200 WM NADPH,
80 WM E. coli Trx-S2, 0.2 mg bovine serum albumin, 0.4 mg human
insulin (Sigma) and 1^3 Wg enzyme. Assay mixtures lacking Trx-S2
served as controls. The change in absorbance at 340 nm was moni-




It was previously reported that PfTrxR can be expressed as
an active His-tag fusion homodimer in the E. coli system [3].
Here we report the expression and puri¢cation of non-fusion
wild-type enzyme and C-terminal mutants. Using the expres-
sion and puri¢cation scheme described above the yield of
recombinant non-fusion proteins was in the range of 4^10
mg pure protein per liter of bacterial culture for the wild-
type and mutant TrxRs. The homogeneity of all proteins
was assessed by SDS-PAGE (data not shown).
3.2. Kinetics of the PfTrxR and mutated enzymes
Reductase activity of wild-type enzyme and mutants was
determined with DTNB and E. coli Trx-S2. The apparent
kinetic parameters of all enzymes are summarized in Table
3. The modi¢cation of the C-terminus had a signi¢cant e¡ect
on the catalytic activity towards DTNB. The Km values of
both PfTrxRC535A and PfTrxRC540A increased about 3-
fold, whereas the speci¢c activities are comparable to that
of the wild-type protein. The double mutation PfTrxRC535A-
C540A raised the Km for this substrate by a factor of 8,
similar to the changes observed for PfTrxRv9, the C-terminal
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Table 1
C-terminal amino acid sequences of various TrxRs and mercuric ion
reductase
Reference
PfTrxR 530AAKGGCGGGKC G Stop [3,23]
HsTrxR 488SGASILQAGCU*G Stop [2,10]
CeTrxR 488SGQDPRTQGCC G Stop [24]
PaMerA 555NKDVKQLSCC AG Stop [25]
EcTrxR 310AERYLDGLADA K Stop [26]
U* represents SeCys.
Table 2
Mutagenic oligonucleotides for site-directed mutagenesis of PfTrxR
5P 1590GCTAAAGGAGGATGTGGGGGTGGAAAATGTGG 3P WT
5P GCTAAAGGAGGAGCTGGGGGTGGAAAATGTGG 3P C535A (S)*
5P CCACATTTTCCACCCCCAGCTCCTCCTTTAGC 3P C535A (AS)*
5P 1605GGGGGTGGAAAATGTGGATAAGGATCCCGGG 3P WT
5P .. .GGGGGTGGAAAAGCTGGATAAGGATCCCGGG 3P C540A (S)
5P .. .CCCGGGATCCTTATCCAGCTTTTCCACCCCC 3P C540A (AS)
5P 1590GCTAAAGGAGGATGTGGGGGTGGAAAATGTGGATAAGGATCCCCG 3P WT
5P GCTAAAGGAGGAGCTGGGGGTGGAAAATGCGGATAAGGATCCCCG 3P C535AC540A(S)
5P CGGGGATCCTTATCCAGCTTTTCCACCCCCAGCTCCTCCTTTAGC 3P C535AC540A(AS)
5P GCGCAAGCTTATGTGTAAAGATAAAAACGAAAAAAAAAATTATG 3P ExHind (S)
5P GCGCGGATCCTTATTTAGCTGCATAAGACAATCC 3P v9 (AS)
Nucleotides that were exchanged in order to obtain the desired mutation are in bold letters. Nucleotides underlined represent start and stop codon,
respectively. Nucleotides in italics represent restriction sites. Numbers in superscript indicate the position of nucleotides in the coding region of the
gene. WT, wild-type, (S), sense; (AS), antisense.
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deletion mutant. Using the kcat/Km ratio as a parameter of
enzyme e⁄ciency, the double mutant and PfTrxRv9 revealed
a 12-fold decrease for DTNB reduction, whereas both single
mutations a¡ected this ratio by a factor of 4. Remarkably, all
mutant proteins were inactive with E. coli Trx-S2 ^ indicating
that both residues are equally important for the reduction of
the peptide substrate thioredoxin ^ whereas the wild-type en-
zyme reacted with a speci¢c activity of 6 U/mg.
3.3. Spectral analysis of PfTrxRC535AC540A
The absorption spectra of PfTrxRC535AC540A are similar
to those of the wild-type protein (Fig. 1). Both proteins have
their absorption maximum at 461 nm in the oxidized state and
show the characteristic £avin spectrum. Upon reduction with
an excess of NADPH, both wild-type enzyme and double
mutant PfTrxRC535AC540A formed a £avin thiolate charge
transfer complex band at 550 nm and revealed a shift in
Vmax to 449 nm. The spectra obtained for both proteins are
almost congruent implying that the C-terminal cysteine resi-
dues of PfTrxR do not interact with the protein bound £avin
as previously reported for the redox-active cysteines of
PfTrxR [5].
4. Discussion
Mammalian TrxRs possess a penultimate SeCys adjacent to
a cysteine residue [4,9,22]. The presence of a SeCys in the
proteins and its location suggest a function of this SeCys/
Cys pair in the catalysis of the mammalian enzyme. As shown
by Arscott et al. [4], this amino acid pair is titratable with
dithionite, probably representing an additional third redox-
active component within the protein. Further, the location
of the additional redox-active residues at the C-terminus of
the protein has implications for the accessibility for possible
interactions with disul¢de substrates during catalysis. These
data are reminiscent of mercuric ion reductases, which also
contain a carboxy-proximal cysteine pair ^ albeit no SeCys
residue ^ involved in the reduction of Hg(II) ions [12^14]. In
mutant proteins of mercuric ion reductase which lack these
Cys residues the DTNB reduction is unimpaired, although the
mercuric ion reductase activity is decreased [12].
PfTrxR, another member of the high Mr TrxRs, shows a
high degree of similarity to the mammalian enzyme, however,
the primary structure at the C-terminus reveals some di¡er-
ences: the parasite amino acid sequence has an extension of
¢ve residues (compared with the human TrxR) and the penul-
timate residue is a normal cysteine rather than a SeCys. The
carboxy-proximal cysteine (Cys540) is separated by four amino
acids from the second cysteine (Cys535), rather than being
located adjacent. It was previously shown that the residues
Cys88 and Cys93 represent the redox-active disul¢de and that
residue His509 ^ located within the C-terminal region of the
protein ^ is most probably the active site base, in analogy to
GR [5]. The knowledge gathered about the importance of the
carboxy-terminal cysteine residues for the catalysis of mercu-
ric ion reductases and the potential role of the penultimate
SeCys/Cys pair for human TrxR as an additional redox-active
component led us to investigate the function of Cys540 and
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Table 3
Apparent kinetic parameters for recombinant wild-type and mutant PfTrxRs
Construct Spec. activity (U/mg) kcat (min31) Km DTNB (mM) kcat/Km (min31 mM31)
WT 10.41 þ 0.1 624 0.49 þ 0.02 1273
C535A 6.49 þ 0.8 390 1.47 þ 0.27 264
C540A 11.3 þ 0.2 678 1.75 þ 0.26 387
C540AC535A 7.15 þ 0.3 429 4.12 þ 0.60 104
PfTrxRv9 6.25 þ 0.7 375 4.07 þ 0.16 92
Data represent means ( þ S.E.M.) of two di¡erent enzyme preparations. The kinetic properties of the recombinant proteins were determined by the
DTNB reduction assay. The mixture (1 ml; 20‡C) consisted of 100 mM potassium phosphate bu¡er, pH 7.6, 0.2 mg/ml bovine serum albumin,
2 mM EDTA, 1^3 Wg/ml recombinant enzyme, 200 WM NADPH and 0.03^5 mM DTNB. The change in absorbance was monitored spectrophoto-
metrically at 412 nm (Uvikon 932, Kontron). The activity was calculated using the molar absorption coe⁄cient of thionitrobenzoate (TNB) at 412
nm (13 600 M31 cm31 per TNB unit).
Fig. 1. A: Spectra of wild-type PfTrxR (in 50 mM potassium phos-
phate bu¡er pH 7.6 containing 1 mM EDTA). a: Oxidized wild-
type PfTrxR (5.9 WM); b: reduced wild-type PfTrxR. Reduction
was achieved by addition of 10 equivalents of NADPH/FAD under
anaerobic conditions. B: Spectra of PfTrxRC535AC540A (in 50
mM potassium phosphate bu¡er pH 7.6 containing 1 mM EDTA).
a: Oxidized PfTrxRC535AC540A (5.6 WM); b: reduced
PfTrxRC535AC540A. Reduction was achieved by addition of 10
equivalents of NADPH/FAD under anaerobic conditions.
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Cys535 for the catalytic activity of PfTrxR. The C-terminal
nine amino acids (Table 1) were deleted, in order to investi-
gate if these residues are functionally involved in catalysis at
all. The protein still shows reactivity with DTNB (Table 3),
but the reducing activity with E. coli Trx-S2 was eliminated.
This signi¢cant e¡ect of the C-terminal deletion suggested that
the C-terminal thiols may be involved in the reduction of the
peptide thioredoxin but are not absolutely necessary for
DTNB reduction. By using site-directed mutagenesis we ad-
dressed the question whether both cysteine residues are ac-
tually involved in this change of reactivity. The characteriza-
tion of the single and double mutant proteins PfTrxRC535A,
PfTrxRC540A and PfTrxRC535AC540A underlines the func-
tion of these thiols in the thioredoxin reduction process. All
three enzymes are not active with E. coli Trx-S2, although
they still show reducing activity with DTNB (Table 3). The
speci¢c activities of the mutant proteins with DTNB as a
substrate are not as much a¡ected as the Km values, which
are drastically increased. The absence of any detectable reduc-
ing activity in all mutant proteins with the peptide substrate
E. coli Trx-S2 suggests that both C-terminal cysteines are cru-
cially involved in substrate coordination and/or electron trans-
fer during reduction of the peptide substrate.
To elucidate the relative topology and the possible interac-
tion of the C-terminal cysteines with the protein bound £avin
the absorbance spectra of the double mutant were investi-
gated. The spectra of the C-terminal mutants and the wild-
type enzyme are remarkably similar, having identical absorb-
ance coe⁄cients and absorbance maxima in both reported
redox states (Fig. 1A,B). The absence of perturbation of the
absorbance spectra of PfTrxRC535AC540A suggests that the
C-terminal cysteines are not in close contact with the isoallox-
azine moiety of the protein bound £avin in contrast to the
redox-active disul¢de (Cys88 and Cys93) as previously reported
for this protein [5]. Whether these cysteine residues are in-
volved in the reduction of the bulky substrate thioredoxin
and/or whether they are responsible for substrate coordina-
tion remains to be further investigated.
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